Back to search
FDAFDA · Food and drugs·Recall number D-0730-2022

TESTOSTERONE CYPIONATE/ANASTROZOLE *GS* OIL 200MG/1MG/ML Injectable, Packaged in a multi dose 10ML vial, as a) 4 ML Formula ID 115387; b) (RM) 10 ML Formula ID 115125; APS Pharmacy

Published April 6, 2022 · Recall initiated: March 23, 2022

Summary

FDA records drug Class II recall D-0730-2022, published April 6, 2022 and initiated March 23, 2022. Recalling firm: Drug Depot, Inc., dba APS Pharmacy; Status: Terminated; Reported quantity: 846 vials; Lot: Lots: a) 745383 BUD: 6/20/2022; 759295 BUD: 8/30/2022; b) 745749 BUD: 6/21/2022; 746272 BUD: 6/27/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of sterility assurance.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Drug Depot, Inc., dba APS Pharmacy
Distributor
Nationwide in the USA including Puerto Rico.
Lot
Lots: a) 745383 BUD: 6/20/2022; 759295 BUD: 8/30/2022; b) 745749 BUD: 6/21/2022; 746272 BUD: 6/27/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was TESTOSTERONE CYPIONATE/ANASTROZOLE *GS* OIL 200MG/1MG/ML Injectable, Packaged in a multi dose 10ML vial, as a) 4 ML Formula ID 115387; b) (RM) 10 ML Formula ID 115125; APS Pharmacy recalled?

Yes. FDA published recall D-0730-2022 on April 6, 2022. Reported hazard: Lack of sterility assurance.

What should I do if I have this product?

Voluntary: Firm initiated · Letter